CoChat

Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study

Open access
Offidani, M, Corvatta, L, Maracci, L, Liberati, A M, Ballanti, S, Attolico, I, Caraffa, P, Alesiani, F, Caravita di Toritto, T, Gentili, S, Tosi, P, Brunori, M, Derudas, D, Ledda, A, Gozzetti, A, Cellini, C, Malerba, L, Mele, A, Andriani, A, Galimberti, S, Mondello, P, Pulini, S, Coppetelli, U, Fraticelli, P, Olivieri, A, Leoni, P · 2013 · Blood Cancer Journal
Cited by 61

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Bendamustine demonstrated synergistic efficacy with bortezomib against multiple myeloma (MM) cells in vitro and seems an effective treatment for relapsed-refractory MM (rrMM). This phase II study evaluated bendamustine plus bortezomib and dexamethasone (BVD) administered over six 28-day cycles and then every 56 days for six further cycles in patients with rrMM treated with 4 prior therapies and not refractory to bortezomib. The primary study end point was the overall response rate after four cycles. In total, 75 patients were enrolled, of median age 68 years. All patients had received targeted agents, 83% had 1-2 prior therapies and 33% were refractory to the last treatment. The response ratepartial response (PR) was 71.5% (16% complete response, 18.5% very good PR, 37% partial remission). At 12 months of follow-up, median time-to-progression (TTP) was 16.5 months and 1-year overall survival was 78%. According to Cox regression analysis, only prior therapy with bortezomib plus lenalidomide significantly reduced TTP (9 vs 17 months; hazard ratio=4.5; P=0.005). The main severe side effects were thrombocytopenia (30.5%), neutropenia (18.5%), infections (12%), neuropathy (8%) and gastrointestinal and cardiovascular events (both 6.5%). The BVD regimen is feasible, effective and well-tolerated in difficult-to-treat patients with rrMM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/bcj.2013.58

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 61

Metadata

Authors
Offidani, M., Corvatta, L., Maracci, L., Liberati, A. M., Ballanti, S., Attolico, I., Caraffa, P., Alesiani, F., Caravita di Toritto, T., Gentili, S., Tosi, P., Brunori, M., Derudas, D., Ledda, A., Gozzetti, A., Cellini, C., Malerba, L., Mele, A., Andriani, A., Galimberti, S., Mondello, P., Pulini, S., Coppetelli, U., Fraticelli, P., Olivieri, A., & Leoni, P.
Venue
Blood Cancer Journal
Published
2013-11-22
Volume
3
Issue
11
Pages
e162-e162
ISSN
2044-5385 (ISSN-L)
OpenAlex
W2022378371
Cited by
61
References
10
FWCI
6.83
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.